Study Stopped
no patient recruitment
Evaluation of Alpha-Lipoic Acid in Diabetic Cardiomyopathy
CARDIALA
Sponsor study identifier
interventional
13
1 country
1
Study Start
November 24, 2020
Actual (reported)Primary Completion
November 1, 2023
Actual (reported)Study Completion
December 1, 2023
Actual (reported)The heart has the ability to respond to different patho-physiological conditions by adapting its energy metabolism. In diabetic subjects, the myocardium uses only fatty acids as a substrate. This is the cause of diabetic cardiomyopathy (DCM). The activation of the transcription factor PPARβ/δ allows a good use of fatty acids. The staff have demonstrated that alpha lipoic acid (AαL), a molecule with antioxidant properties present in food supplements and in certain foods (broccoli, cabbage, offal...), induces the expression of PPARβ/δ in skeletal muscle and thus increases the activity of this transcription factor.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 1, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 25, 2019
Actual (reported)October 28, 2019
Actual (reported)November 24, 2020
Actual (reported)November 1, 2023
Actual (reported)December 1, 2023
Actual (reported)change of LVEF between before and after 12 weeks of treatment
percentage of blood ejection before and after 12 weeks of treatment
12 weeks
1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
Nice Hospital
Nice, 06000, France
13 participants (actual enrollment reported by the registry).
First Submitted
October 25, 2019
First Posted
October 28, 2019
Study Start
November 24, 2020
Actual (reported)Single-center Clinical Study of Early Diagnosis of Diabetic Cardiomyopathy With FLIM
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
November 1, 2023
Actual (reported)Study Completion
December 1, 2023
Actual (reported)Last Updated
February 5, 2024
Record last verified: 2024-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: